60 Degrees Pharmaceuticals, Inc. (SXTP)
NASDAQ:SXTP
Want to see SXTP full AI Analyst Report?
Top Page
60 Degrees Pharmaceuticals, Inc.
(NASDAQ:SXTP)
Select Model
Select Model
Rating:42Neutral
Price Target:
$1.50
▲(200.00% Upside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by weak financial performance (large recurring losses and significant, worsening cash burn relative to modest revenue), with bearish technicals reinforcing downside risk. Valuation contributes limited support because the negative P/E reflects unprofitable operations and there is no indicated dividend yield.
Positive Factors
Low Leverage / Positive Equity
The company’s balance sheet shows minimal debt and positive equity (~$4.7M), which reduces bankruptcy risk and preserves financial flexibility. This structural strength gives management time to execute R&D and commercialization plans versus a highly leveraged peer.
Negative Factors
Severe Cash Burn
Sustained negative operating and free cash flow (~-$8.2M TTM) is a structural threat to runway and forces reliance on external financing. Persistent cash burn constrains R&D, commercial expansion and increases likelihood of dilutive raises absent near-term material revenue growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Positive Equity
The company’s balance sheet shows minimal debt and positive equity (~$4.7M), which reduces bankruptcy risk and preserves financial flexibility. This structural strength gives management time to execute R&D and commercialization plans versus a highly leveraged peer.
Read all positive factors
60 Degrees Pharmaceuticals, Inc. (SXTP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.96M
Dividend YieldN/A
Average Volume (3M)199.18K
Price to Earnings (P/E)―
Beta (1Y)2.43
Revenue Growth66.12%
EPS Growth91.75%
CountryUS
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-10.15
Shares Outstanding2,659,288
10 Day Avg. Volume488,900
30 Day Avg. Volume199,179
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)1.35
P/FCF Ratio-0.19
Enterprise Value/Market Cap-0.50
Enterprise Value/Revenue-1.98
Enterprise Value/Gross Profit-9.45
Enterprise Value/Ebitda0.26
Forecast
1Y Price Target
$4.20Price Target Upside740.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-3.16
Revenue Forecast (FY)$1.30M
60 Degrees Pharmaceuticals, Inc. Business Overview & Revenue Model
Company Description
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevent...
How the Company Makes Money
null...
60 Degrees Pharmaceuticals, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
14
Very Negative
| Breakdown | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.01M | 607.57K | 253.57K | 223.21K | 1.16M |
| Gross Profit | 223.78K | 222.81K | -220.98K | -209.16K | 309.60K |
| EBITDA | -7.28M | -7.88M | -1.43M | -2.11M | -1.01M |
| Net Income | -7.37M | -7.95M | -3.77M | -6.18M | -4.25M |
Balance Sheet | |||||
| Total Assets | 5.37M | 5.76M | 7.78M | 1.30M | 1.39M |
| Cash, Cash Equivalents and Short-Term Investments | 2.75M | 3.39M | 2.14M | 264.87K | 115.40K |
| Total Debt | 152.78K | 155.89K | 172.67K | 22.42M | 18.80M |
| Total Liabilities | 1.99M | 1.80M | 2.99M | 25.45M | 19.55M |
| Stockholders Equity | 3.46M | 4.04M | 4.87M | -23.58M | -17.58M |
Cash Flow | |||||
| Free Cash Flow | -7.07M | -5.83M | -4.66M | -1.07M | -684.50K |
| Operating Cash Flow | -6.85M | -5.65M | -4.54M | -1.01M | -649.11K |
| Investing Cash Flow | 254.92K | -1.89M | -115.89K | -60.13K | -35.39K |
| Financing Cash Flow | 6.44M | 7.05M | 6.47M | 1.22M | 611.23K |
60 Degrees Pharmaceuticals, Inc. Technical Analysis
Negative
0.50
Price Trends
1.65
Negative
2.37
Negative
3.62
Negative
Market Momentum
-0.08
Negative
44.91
Neutral
43.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SXTP, the sentiment is Negative. The current price of 0.5 is below the 20-day moving average (MA) of 1.51, below the 50-day MA of 1.65, and below the 200-day MA of 3.62, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 44.91 is Neutral, neither overbought nor oversold. The STOCH value of 43.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SXTP.
60 Degrees Pharmaceuticals, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
42 Neutral | $3.96M | -0.33 | -212.63% | ― | 66.12% | 91.75% | |
| ― | $2.73M | -0.26 | -168.95% | ― | ― | 84.00% | |
41 Neutral | $41.46M | -0.91 | -1335.64% | ― | ― | 66.47% | |
| ― | $1.38M | -0.07 | -263.57% | ― | -61.81% | 99.68% |
* Healthcare Sector Average
SXTP
60 Degrees Pharmaceuticals, Inc.
1.46
-9.82
-87.06%
OGEN
Oragenics
0.61
-4.40
-87.92%
KALA
KALA BIO
2.20
-173.55
-98.75%
KTTA
Pasithea Therapeutics Corp
0.72
-0.22
-23.12%
SPRC
SciSparc Ltd.
10.59
-49.13
-82.27%
ONCO
Onconetix
1.14
-338.86
-99.66%
60 Degrees Pharmaceuticals, Inc. Corporate Events
Regulatory Filings and ComplianceStock Split
60 Degrees Updates Affiliate Share Ownership Disclosure Error
Neutral
Mar 20, 2026
On March 20, 2026, 60 Degrees Pharmaceuticals, Inc. reported that it had miscalculated the number of shares of common stock beneficially owned by a company affiliate in a prospectus supplement dated March 13, 2026. The affiliate’s holdings w...
Private Placements and FinancingRegulatory Filings and Compliance
60 Degrees Pharmaceuticals Updates Legal Opinion for ATM Offering
Neutral
Mar 13, 2026
On March 13, 2026, 60 Degrees Pharmaceuticals, Inc. filed an updated legal opinion covering the shares of common stock issued and sold under its at-the-market equity offering program with HC Wainwright Co., LLC, originally established under a Sep...
Private Placements and FinancingRegulatory Filings and Compliance
60 Degrees Pharmaceuticals Updates Opinion for ATM Program
Positive
Mar 12, 2026
On March 12, 2026, 60 Degrees Pharmaceuticals, Inc. filed an updated legal opinion of counsel covering shares of common stock issued and sold under its at-the-market equity offering program established under a September 5, 2025 sales agreement wit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.